IMMvention is moving BACH1 inhibitors through preclinical development. The oral small molecules could induce fetal hemoglobin expression. Other companies have hit on the idea of treating sickle ...

FANCJ, also known as BACH1 or BRIP1, was identified as a direct BRCA1-BRCT interacting protein and functions in DNA repair and checkpoint control. Bi-allelic inheritance of mutations in FANCJ ...

IMMvention over the past few years has focused on pursuing an oral therapy for sickle cell disease by targeting a specific protein, called BACH1, involved in sickle cell and other diseases.

Immvention Therapeutix is partnering with Novo Nordisk to develop oral treatments for sickle cell disease (SCD) and other ...

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

BACH1 is thought to be a key regulator of cellular responses, oxidative stress, and inflammation in multiple disease states, making it a promising therapeutic target.

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

The product of the BRCA1 gene — germline mutations in which confer an increased risk of breast or ovarian cancer — has been implicated in the repair of double-stranded DNA breaks (DSBs).